J. Cehelsky

发表

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.

N. Svrzikapa, G. Shapiro, P. LoRusso, 2013, Cancer discovery.

Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC)

Tracy S. Zimmermann, J. Gollob, R. Falzone, 2013 .

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Rob Lambkin-Williams, E. Walsh, J. Gollob, 2010, Proceedings of the National Academy of Sciences.

Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

J. Oxford, Rob Lambkin-Williams, A. Mann, 2010, American journal of respiratory and critical care medicine.

Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus

Young-In Kim, R. Álvarez, J. Devincenzo, 2014, PloS one.

Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

J. Heymach, G. Shapiro, H. Burris, 2010 .

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

N. Svrzikapa, G. Shapiro, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

E. Walsh, B. Bagga, J. Devincenzo, 2015, The Journal of infectious diseases.

Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia

J. Ritter, L. Nechev, K. Fitzgerald, 2012, Arteriosclerosis, Thrombosis, and Vascular Biology.

Preclinical and Clinical Studies Employing RNA Interference as a Therapeutic for Respiratory Syncytial Virus (RSV) Infection in the Lung

J. Gollob, R. Meyers, J. Cehelsky, 2013 .

Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients

M. Zamora, J. Gollob, J. Gottlieb, 2012 .

Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP) (S38.003)

B. Bettencourt, K. Gruis, J. Gollob, 2016 .

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.

B. Bettencourt, M. Zamora, J. Gollob, 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

B. Bettencourt, P. Lozeron, P. Hawkins, 2013, The New England journal of medicine.

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.

M. Maitland, C. Kyratsous, D. Lebwohl, 2021, The New England journal of medicine.

RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.

M. Zamora, A. Humar, J. Gollob, 2011, American journal of respiratory and critical care medicine.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

B. Bettencourt, Svetlana Shulga-Morskaya, J. Gollob, 2014, The Lancet.

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

S. Elbashir, J. Harborth, I. Toudjarska, 2008, Antiviral research.

Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy.

G. Shapiro, P. LoRusso, J. Tabernero, 2012 .

Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants

A. Patters, J. Devincenzo, J. Cehelsky, 2012, ISRN pediatrics.

Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group

S. Steinberg, F. Balis, B. Widemann, 2006, Cancer Chemotherapy and Pharmacology.

ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis

P. Lozeron, L. Nechev, P. Hawkins, 2011 .

Results of a phase 2b multi-center, randomized, double-blind, placebo-controlled study of an RNAi therapeutic, ALN-RSV01, in respiratory syncytial virus (RSV)-infected lung transplant patients

M. Zamora, J. Gollob, J. Gottlieb, 2012 .